1. Clinical Overview
Buprenorphine is a semi-synthetic opioid analgesic derived from thebaine. At the 0.3mg strength, it is primarily indicated for the management of moderate to severe acute pain. It is a partial mu-opioid receptor agonist and a kappa-opioid receptor antagonist, offering a unique pharmacological profile with a ceiling effect on respiratory depression, making it potentially safer than full agonists in certain contexts. In India, it is a critical component of pain management protocols and is also used in opioid dependence treatment at higher doses.
| Onset | Duration | Bioavailability |
|---|---|---|
| Sublingual: 30-60 minutes; Intramuscular/Intravenous: 15-30 minutes. | Approximately 6-8 hours for analgesic effect. | Sublingual: 30-55%; Intramuscular: High (near 100%). |
2. Mechanism of Action
Buprenorphine binds with high affinity to central nervous system mu-opioid receptors (MOR) and kappa-opioid receptors (KOR). At the MOR, it acts as a partial agonist, producing analgesic and subjective effects but with a ceiling (plateau) effect. At the KOR, it acts as an antagonist, which may contribute to a lower incidence of dysphoria and psychotomimetic effects compared to some other opioids.
3. Indications & Uses
- Management of moderate to severe acute pain (e.g., post-operative pain, trauma, renal colic)
- Management of chronic pain (as part of a comprehensive pain management plan)
4. Dosage & Administration
Adult Dosage: For Pain (Sublingual/IM): 0.3mg every 6-8 hours as needed for pain. Dose may be repeated once in 30-60 minutes if needed. Usual range: 0.3mg - 0.6mg per dose. For Opioid Dependence: Not applicable at this low strength; higher fixed-dose combinations (e.g., with naloxone) are used.
Administration: Sublingual Tablet: Place under the tongue until completely dissolved (5-10 minutes). Do not chew, swallow, or talk while tablet dissolves. Avoid eating or drinking for 15 minutes after administration. Intramuscular Injection: Administer deep IM into a large muscle mass. Rotate injection sites.
5. Side Effects
Common side effects may include:
- Nausea
- Vomiting
- Constipation
- Drowsiness/Sedation
- Dizziness
- Headache
- Sweating
- Dry mouth
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Benzodiazepines (e.g., Alprazolam, Diazepam) | Profound sedation, respiratory depression, coma, and death. | Major |
| Other CNS Depressants (Alcohol, Barbiturates, Sedative-hypnotics) | Additive CNS and respiratory depression. | Major |
| Other Opioid Agonists (Morphine, Fentanyl, Codeine) | Buprenorphine may block effects or precipitate withdrawal due to its high receptor affinity. | Major |
| CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | Increased buprenorphine plasma levels, risk of toxicity. | Moderate |
| CYP3A4 Inducers (Rifampicin, Carbamazepine, Phenytoin, St. John's Wort) | Decreased buprenorphine plasma levels, reduced efficacy, potential withdrawal. | Moderate |
| Serotonergic Drugs (SSRIs, SNRIs, TCAs, Tramadol) | Increased risk of serotonin syndrome. | Moderate |
| Anticholinergics | Increased risk of urinary retention and severe constipation. | Moderate |
| MAO Inhibitors | Potentially fatal serotonin syndrome or opioid toxicity; contraindicated. | Contraindicated |
7. Patient Counselling
- DO take exactly as prescribed. Do not increase dose or frequency without consulting your doctor.
- DO inform all your healthcare providers (doctors, dentists) that you are taking this medicine.
- DO store the medicine securely, out of sight and reach of children and others for whom it is not prescribed.
- DO dispose of unused tablets safely.
- DON'T crush, chew, or swallow the sublingual tablet whole. Let it dissolve under your tongue.
- DON'T consume alcohol or sleep-inducing medications (without doctor's advice) while on this drug.
- DON'T drive or operate heavy machinery until you know how this medicine affects you.
- DON'T stop taking the medicine abruptly if used long-term; taper under medical supervision to avoid withdrawal.
8. Toxicology & Storage
Overdose: Pinpoint pupils, respiratory depression (may be less severe than with full agonists), somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, bradycardia, hypotension, circulatory collapse, cardiac arrest, death.
Storage: Store at room temperature (15-30°C), protected from light and moisture. Keep in the original blister pack or container. Keep out of reach and sight of children and pets. Do not flush unused medication. Dispose of as per local regulations for controlled substances (e.g., return to pharmacy).